PARP inhibitors in the treatment of metastatic breast cancer patients with germline BRCA1/2 mutations. Experience of treatment with talazoparib in clinical practice

Germline BRCA1/2 mutations account for about 10% of all breast cancer. BRCA1/2 proteins are involved in homologous recombination - DNA double-strand break repair mechanism. Poly-(ADP ribose) polymerases (PARP) are required to repair DNA single-strand breaks through base excision repair. PARP inhibitors represent a modern option of treatment of metastatic HER2 negative breast cancer with germline BRCA1/2 mutations. Mechanism of action of PARP inhibitors is based on the concept of synthetic lethality under conditions of BRCA dysfunction, when both DNA repair mechanisms, homologous recombination and base excision repair, are impaired. This leads to the apoptosis of cancer cells. Currently two PARP inhibitors are registered in Russia for the treatment of BRCA-associated metastatic HER2 negative breast cancer – olaparib and talazoparib. Efficacy of PARP inhibitors olaparib and talazoparib versus standard chemotherapy has been studied in very similarly designed phase III trials OlympiAD и EMBRACA. Benefit in the progression free survival, acceptable toxicity profile and positive impact on quality of life support inclusion of PARP inhibitors in treatment schemes of metastatic BRCAassociated breast cancer. Very important is the role of PARP inhibitors in treatment of very aggressive triple negative breast cancer with limited number of effective therapy options. We represent here a clinical case of treatment of metastatic triple negative breast cancer with talazoparib in 4th line of therapy.

• Publication year

  2020

• Venue

  Meditsinskiy sovet = Medical Council

• Publication date

  2020-07-30

• Fields of study

  Not labeled

• Identifiers
  DOI 10.21518/2079-701x-2020-9-57-61
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• A bibliometric analysis of the top 100 most cited papers and research trends in breast cancer related BRCA1 and BRCA2 genes

  2022cited by this paper
• Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician’s Choice Standard-of-Care Chemotherapy

  2019cited by this paper
• Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis

  2018cited by this paper
• Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

  2018cited by this paper
• ЭТНИЧЕСКИЕ ОСОБЕННОСТИ ФОРМИРОВАНИЯ ГЕНЕТИЧЕСКОЙ ПРЕДРАСПОЛОЖЕННОСТИ К РАЗВИТИЮ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ, "Генетика"

  2018cited by this paper
• The multifaceted roles of PARP1 in DNA repair and chromatin remodelling

  2017cited by this paper
• PARP inhibitors: Synthetic lethality in the clinic

  2017cited by this paper
• Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.

  2017cited by this paper
• Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers

  2017cited by this paper
• Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action

  2016cited by this paper
• Наследственный рак молочной железы

  2016cited by this paper
• Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer.

  2015cited by this paper
• Применение методов распознавания образов для оценки индивидуальной предрасположенности к раку молочной железы

  2015cited by this paper
• Beyond BRCA: new hereditary breast cancer susceptibility genes.

  2015cited by this paper
• Наследственный рак молочной железы: генетическая и клиническая гетерогенность, молекулярная диагностика, хирургическая профилактика в группах риска

  2015cited by this paper
• Association of BRCA1 germline mutations in young onset triple-negative breast cancer (TNBC)

  2014cited by this paper
• Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing

  2014cited by this paper
• BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency

  2013cited by this paper
• A Comprehensive Focus on Global Spectrum of BRCA1 and BRCA2 Mutations in Breast Cancer

  2013cited by this paper
• Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib

  2013cited by this paper
• BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years

  2012cited by this paper
• Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.

  2012cited by this paper
• Safety and efficacy results from two randomized expansions of a phase I study of a tablet formulation of the PARP inhibitor, olaparib, in ovarian and breast cancer patients with BRCA1/2 mutations.

  2012cited by this paper
• Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer

  2011cited by this paper
• Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)

  2011cited by this paper
• Relative contributions of BRCA1 and BRCA2 mutations to “triple-negative” breast cancer in Ashkenazi Women

  2011cited by this paper
• A phase I study to determine the comparative bioavailability of two different oral formulations of the PARP inhibitor, olaparib (AZD2281), in patients with advanced solid tumors.

  2010cited by this paper
• Clinical and Pathologic Characteristics of Patients With BRCA-Positive and BRCA-Negative Breast Cancer

  2009cited by this paper
• The prevalence of BRCA1 mutations among young women with triple-negative breast cancer

  2009cited by this paper
• Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

  2009cited by this paper
• Targeted therapy for cancer using PARP inhibitors.

  2008cited by this paper
• A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair.

  2008cited by this paper
• Current Development of Clinical Inhibitors of Poly(ADP-Ribose) Polymerase in Oncology

  2007cited by this paper
• BRCA1: mechanisms of inactivation and implications for management of patients.

  2002cited by this paper
• Search for Frequent Mutations in Genes Predisposing to Breast Cancer

  2001cited by this paper
• Hereditary breast cancer.

  1991cited by this paper

• No citing papers are available for this paper.